

**Date and Time:** 9<sup>th</sup> July 2013 (10.00 – 4.30pm)

**Minutes:** confirmed

**Guideline Development Group Meeting 2: Coeliac disease**

**Place:** NICE offices – Piccadilly Plaza, Manchester

**Present:** Damien Longson (Chair) (DL)  
Mohamed Abuzak (MA)  
Steph Briggs (SB)  
Martin Dadswell (MD)  
Berne Ferry (BF)  
Mike Forrest (MF)  
Peter Gillett (PG)  
Anne Holdoway (AH)  
Norma McGough (NM)  
Simon Murch (SM)  
David Sanders (DS)  
Rita Shergill-Bonner (RSB)  
Jeremy Woodward (JW)

**Apologies** Sorrell Burden (SB)  
Rajeev Gupta (RG)  
Gerry Robins (GR)

**In attendance:**

<p>NICE Staff:</p> <p>Emma Banks (EB) Ben Doak (BD) Sue Ellerby (SE) Sarah Glover (SG) Michael Heath (MH)</p>	<p>Rachel Houten (RH) Gabriel Rogers (GR) Heather Stegenga Toni Tan (TT)</p>	<p>Observers:</p> <p>Joy Carvill Michelle Gilberthorpe Robby Richey</p>
---	--	---

**Notes**

- DL welcomed the group to the 2<sup>nd</sup> meeting of this GDG. Apologies were received from SB, RG and GR. New conflicts of interest were received from AH and RH, these were documented and the Chair confirmed both could remain in the meeting and participate. Minutes for the previous meeting were agreed.
- HS presented the review protocols for remaining review questions to be addressed within the development of the guideline. The GDG discussed the inclusion and exclusion criteria for each question and agreed the review protocols.

3. SG gave a presentation on how literature searches are undertaken and developed, providing examples of the types of sources used to carry out this work. She then went onto discuss in more detail how the literature search for RQK was completed.
4. TT provided an overview of the method of Grading of Recommendations, Assessment, Development and Evaluation (GRADE). This process is used for grading evidence and recommendations in a transparent way and helps to protect against errors, resolve disagreements and facilitates critical appraisal whilst enabling information to be communicated clearly. Using this methodology, the clinical evidence was then presented and discussed with input from a health economics perspective for RQK on the effectiveness of autologous stem cell transplant for people with refractory coeliac disease.
5. RH led a discussion with the GDG to finalise which clinical review questions within this care pathway they felt would benefit the most from health economic input and the types of economic modelling that may be appropriate. She finished by asking a number of questions for clarification on the different health states within the condition.
6. HS returned to the review protocols to continue discussing their content and agree the inclusion and exclusion criteria with the GDG for each review question.
7. As an AOB item the group were asked if any co-opted experts were needed during development to provide additional evidence from their experience and specific expertise to help the GDG make decisions. It was agreed they would not be needed at this time.

### **Date, time and venue of the next meeting**

10am – 30<sup>th</sup> September & 1<sup>st</sup> October – NICE Offices – Manchester.